Randomized trial · people
Amycretin: side effects all mild or moderate in first human trial
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This is the first human safety data for oral amycretin. Side effects were mild or moderate and mostly gut-related, but the study does not establish how much weight the drug takes off.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 144
- Published
- 2025
- Journal
- Lancet
What they tested
The team tested whether amycretin tablets, a single molecule that acts on both GLP-1 and amylin receptors, were safe and well tolerated in people for the first time, and how the drug's blood levels behaved across doses.
How the study was done
A randomized, double-blind, placebo-controlled phase 1 trial in 144 adults aged 18-55 with overweight or obesity at one research site in San Antonio, Texas. It had three parts: single doses from 1 mg to 25 mg, daily doses of 3 mg, 6 mg or 12 mg for 10 days, and a 12-week regimen with doses stepped up as high as 2 × 50 mg a day, each compared against placebo (a dummy tablet).

Model. Individual results vary.
What they found
Across all parts, 89 (62%) of 144 people had at least one adverse event, meaning any health problem that came up during the study, with 364 events in total. Every event was mild or moderate, and events became more common at higher doses. Gastrointestinal events were the most common type, making up 180 (49%) of the 364 events and affecting 72 (81%) of the 89 people who had any event. There were no deaths, and amycretin blood levels rose in proportion to the dose.
What it doesn’t show
This was a small, early safety trial at a single site, lasting at most 12 weeks of treatment. Its main goal was safety rather than weight loss. Weight and blood sugar were only exploratory measures, and the study was funded by Novo Nordisk.
The paper
Gasiorek et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet. 2025.
The compound
More studies on Amycretin
- Amycretin: oral 50 mg arm cut HbA1c by 1.4% at 36 weeksRandomized trial · people · 2026
- Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetesRandomized trial · people · 2026
- Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trialRandomized trial · people · 2025
- Amycretin: similar drug exposure with kidney impairment in phase 1Clinical trial · people · 2026
- Amycretin cut body weight by 18% in obese rats over 21 daysAnimal study · mice and rats · 2025
- Every study on Amycretin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.